Cognition Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Cognition Therapeutics, Inc. (CGTX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $319.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-07
- Cognition Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $319.00K, a 48.63% decline year-over-year.
- Cognition Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $330.00K, a 43.69% decline year-over-year.
- Cognition Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $522.00K, a 41.74% decline year-over-year.
- Cognition Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $621.00K, a 45.86% decline year-over-year.
- Cognition Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $2.09M, a 2445.12% increase from fiscal 2024.
- Cognition Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $82.00K, a 98.12% decline from fiscal 2023.
- Cognition Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $4.35M, a 21.89% increase from fiscal 2022.
- Cognition Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $3.57M, a 31.08% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $319.00K 10-Q · filed 2026-08-07 | $649.00K derived: sum of 2 quarters · filed 2026-08-07 | |||
| 2026-03-31 | $330.00K 10-Q · filed 2026-08-07 | ||||
| 2025-12-31 | $2.09M 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | $522.00K 10-Q · filed 2025-11-06 | $1.14M derived: sum of 2 quarters · filed 2026-08-07 | $1.73M derived: sum of 3 quarters · filed 2026-08-07 | ||
| 2025-06-30 | $621.00K 10-Q · filed 2026-08-07 | $1.21M derived: sum of 2 quarters · filed 2026-08-07 | |||
| 2025-03-31 | $586.00K 10-Q · filed 2026-08-07 | ||||
| 2024-12-31 | $82.00K 10-K · filed 2026-03-26 | $3.75M 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $896.00K 10-Q · filed 2025-11-06 | $2.04M derived: sum of 2 quarters · filed 2025-11-06 | $3.21M derived: sum of 3 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $1.15M 10-Q · filed 2025-11-06 | $2.32M derived: sum of 2 quarters · filed 2025-11-06 | |||
| 2024-03-31 | $1.17M 10-Q · filed 2025-11-06 | ||||
| 2023-12-31 | $4.35M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $1.07M 10-Q · filed 2024-11-13 | $2.10M derived: sum of 2 quarters · filed 2024-11-13 | $3.28M derived: sum of 3 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $1.02M 10-Q · filed 2024-11-13 | $2.21M derived: sum of 2 quarters · filed 2024-11-13 | |||
| 2023-03-31 | $1.19M 10-Q · filed 2024-11-13 | ||||
| 2022-12-31 | $3.57M 10-K · filed 2024-03-26 | ||||
| 2022-09-30 | $777.00K 10-Q · filed 2023-11-02 | $1.67M derived: sum of 2 quarters · filed 2023-11-02 | $2.67M derived: sum of 3 quarters · filed 2023-11-02 | ||
| 2022-06-30 | $892.00K 10-Q · filed 2023-11-02 | $1.89M derived: sum of 2 quarters · filed 2023-11-02 | |||
| 2022-03-31 | $1.00M 10-Q · filed 2023-11-02 | ||||
| 2021-12-31 | $5.18M 10-K · filed 2023-03-23 | ||||
| 2021-09-30 | $72.00K 10-Q · filed 2022-11-14 | $166.00K derived: sum of 2 quarters · filed 2022-11-14 | $264.00K derived: sum of 3 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $94.00K 10-Q · filed 2022-11-14 | $192.00K derived: sum of 2 quarters · filed 2022-11-14 | |||
| 2021-03-31 | $98.00K 10-Q · filed 2022-11-14 | ||||
| 2020-12-31 | $475.00K 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | $129.00K 10-Q · filed 2021-11-17 | $217.00K derived: sum of 2 quarters · filed 2021-11-17 | $342.00K derived: sum of 3 quarters · filed 2021-11-17 | ||
| 2020-06-30 | $88.00K 10-Q · filed 2021-11-17 | $213.00K derived: sum of 2 quarters · filed 2021-11-17 | |||
| 2020-03-31 | $125.00K 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |